Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Polymorphism, Single Nucleotide*; Brain-Derived Neurotrophic Factor/*blood ; Brain-Derived Neurotrophic Factor/*genetics ; Diabetes Mellitus, Type 2/*complications ; Diabetic Neuropathies/*blood ; Diabetic Neuropathies/*genetics; Adult ; Aged ; Amino Acid Substitution ; Biomarkers/blood ; Case-Control Studies ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/genetics ; Female ; Genetic Predisposition to Disease ; Genotype ; Humans ; Male ; Methionine/genetics ; Middle Aged ; Peripheral Nervous System Diseases/blood ; Peripheral Nervous System Diseases/complications ; Peripheral Nervous System Diseases/genetics ; Valine/genetics

Background: Studies by our group demonstrated brain-derived neurotrophic factor (BDNF) levels in blood and BDNF-Val66met-SNP as potential biomarkers in chemotherapy-induced peripheral neuropathy. Here, we evaluate symptoms of peripheral neuropathy (PN) and depression in patients with type II diabetes mellitus in search of an association with serum BDNF levels and the Val66Met-SNP.
Methods: In total, 90 patients enrolled in the study; 23 (25.6%) had known PN, as determined by nerve conduction studies (NCS-PN), and 67 (74.4%) were not diagnosed with PN (U-PN). PN symptoms were assessed and graded in these groups using the total neuropathy score (TNSr) and DN4 scales. Small nerve fiber testing of sensitivity thresholds to cold, warm and hot pain signals was performed using the Q-sense device. Depression was assessed using the PHQ9 questionnaire. BDNF protein levels and Val66Met-SNP were determined with ELISA and Sanger sequencing, respectively.
Results: NCS-PN patients showed lower serum BDNF levels alongside significantly higher TNSr, DN4 and PHQ9 scores and lower hot pain sensitivity thresholds as compared to U-PN patients. Patients with Met-BDNF-SNP showed increased TNSr scores and lower hot pain sensitivity thresholds as compared to patients with Val-BDNF-SNP. Depression showed a weaker correlation with sensitivity thresholds to hot pain signals as compared to TNSr and DN4 scores.
Conclusions: Diminished peripheral BDNF resources and Met-BDNF-SNP genotype are associated with augmented symptoms of PN in patients with type II diabetes mellitus. Sensitivity thresholds to hot pain signals may be less influenced by depression and possibly more accurately detect PN symptoms in diabetic patients.

Johnson JE, Barde YA, Schwab M, Thoenen H (1986) Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. J Neurosci 6(10):3031–3038. (PMID: 10.1523/JNEUROSCI.06-10-03031.1986)
Yamamoto H, Gurney ME (1990) Human platelets contain brain-derived neurotrophic factor. J Neurosci 10(11):3469–3478. (PMID: 10.1523/JNEUROSCI.10-11-03469.1990)
Fujimura H, Altar CA, Chen R et al (2002) Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemostasis 87(4):728–734. (PMID: 10.1055/s-0037-1613072)
Chacon-Fernandez P, Sauberli K, Colzani M, Moreau T, Ghevaert C, Barde YA (2016) Brain-derived neurotrophic factor in megakaryocytes. J Biol Chem 291(19):9872–9881. (PMID: 10.1074/jbc.M116.720029)
Kerschensteiner M, Gallmeier E, Behrens L et al (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189(5):865–870. (PMID: 10.1084/jem.189.5.865)
Azoulay D, Urshansky N, Karni A (2008) Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 195(1–2):186–193. (PMID: 10.1016/j.jneuroim.2008.01.010)
Azoulay D, Vachapova V, Shihman B, Miler A, Karni A (2005) Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 167(1–2):215–218. (PMID: 10.1016/j.jneuroim.2005.07.001)
Egan MF, Kojima M, Callicott JH et al (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257–269. (PMID: 10.1016/S0092-8674(03)00035-7)
Bialecka M, Kurzawski M, Roszmann A et al (2014) BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease. Neurosci Lett 561:86–90. (PMID: 10.1016/j.neulet.2013.12.051)
Borroni B, Archetti S, Costanzi C et al (2009) Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging 30(9):1406–1412. (PMID: 10.1016/j.neurobiolaging.2007.11.023)
Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50(2):431–438. (PMID: 10.1007/s00125-006-0537-4)
Fujinami A, Ohta K, Obayashi H et al (2008) Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: Relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem 41(10–11):812–817. (PMID: 10.1016/j.clinbiochem.2008.03.003)
de la Monte SM (2017) Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer's disease. Drugs 77(1):47–65. (PMID: 10.1007/s40265-016-0674-0)
Seki M, Tanaka T, Nawa H et al (2004) Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53(9):2412–2419. (PMID: 10.2337/diabetes.53.9.2412)
Andreassen CS, Jakobsen J, Flyvbjerg A, Andersen H (2009) Expression of neurotrophic factors in diabetic muscle–relation to neuropathy and muscle strength. Brain 132(10):2724–2733. (PMID: 10.1093/brain/awp208)
Azoulay D, Leibovici A, Sharoni R et al (2015) Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 153(3):703–704. (PMID: 10.1007/s10549-015-3546-5)
Azoulay D, Lavie D, Horowitz N et al (2014) Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol 164(3):454–456. (PMID: 10.1111/bjh.12624)
Azoulay D, Nasser R, Sharon R et al (2018) Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma. Br J Haematol 185:175–177. (PMID: 10.1111/bjh.15428)
Azoulay D, Giryes S, Nasser R, Sharon R, Horowitz NA (2019) Prediction of chemotherapy-induced peripheral neuropathy in patients with Lymphoma and Myeloma: the roles of brain-derived neurotropic factor protein levels and a gene polymorphism. J Clin Neurol 15(4):511–516. (PMID: 10.3988/jcn.2019.15.4.511)
Leibovici A, Sharon R, Azoulay D (2018) BDNF Val66Met is associated with pre-existing but not with Paclitaxel-induced peripheral neuropathy in an Israeli cohort of breast cancer patients. Isr Med Assoc J IMAJ 20(12):746–748. (PMID: 30550003)
Smith EM, Beck SL, Cohen J (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35(1):96–102. (PMID: 10.1188/08.ONF.96-102)
Celik S, Yenidunya G, Temel E et al (2016) Utility of DN4 questionnaire in assessment of neuropathic pain and its clinical correlations in Turkish patients with diabetes mellitus. Prim Care Diabetes 10(4):259–264. (PMID: 10.1016/j.pcd.2015.11.005)
Hovaguimian A, Gibbons CH (2011) Diagnosis and treatment of pain in small-fiber neuropathy. Curr Pain Headache Rep 15(3):193–200. (PMID: 10.1007/s11916-011-0181-7)
Gilbody S, Richards D, Brealey S, Hewitt C (2007) Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 22(11):1596–1602. (PMID: 10.1007/s11606-007-0333-y)
Perkins BA, Olaleye D, Zinman B, Bril V (2001) Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 24(2):250–256. (PMID: 10.2337/diacare.24.2.250)
Tracy JA, Dyck PJ (2008) The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am 19(1):1–26. (PMID: 10.1016/j.pmr.2007.10.010)
Bouhassira D, Letanoux M, Hartemann A (2013) Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLOS ONE 8(9):e74195. (PMID: 10.1371/journal.pone.0074195)
Kramer HH, Rolke R, Bickel A, Birklein F (2004) Thermal thresholds predict painfulness of diabetic neuropathies. Diabetes Care 27(10):2386–2391. (PMID: 10.2337/diacare.27.10.2386)
Lustman PJ, Clouse RE (2005) Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complic 19(2):113–122.
Sharif S, Raza MT, Mushtaq S, Afreen B, Hashmi BA, Ali MH (2019) Frequency of depression in patients with type 2 diabetes mellitus and its relationship with glycemic control and diabetic microvascular complications. Cureus 11(7):e5145. (PMID: 315235736741377)
Vileikyte L, Leventhal H, Gonzalez JS et al (2005) Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care 28(10):2378–2383. (PMID: 10.2337/diacare.28.10.2378)
Zaslansky R, Yarnitsky D (1998) Clinical applications of quantitative sensory testing (QST). J Neurol Sci 153(2):215–238. (PMID: 10.1016/S0022-510X(97)00293-1)
Shukla G, Bhatia M, Behari M (2005) Quantitative thermal sensory testing—value of testing for both cold and warm sensation detection in evaluation of small fiber neuropathy. Clin Neurol Neurosurg 107(6):486–490. (PMID: 10.1016/j.clineuro.2004.12.016)
Azoulay D, Nasser R, Sharon R et al (2019) Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma. Br J Haematol 185(1):175–177. (PMID: 10.1111/bjh.15428)
Pliego-Rivero FB, Bayatti N, Giannakoulopoulos X et al (1997) Brain-derived neurotrophic factor in human platelets. Biochem Pharmacol 54(1):207–209. (PMID: 10.1016/S0006-2952(97)00073-7)
Tamura S, Suzuki H, Hirowatari Y et al (2011) Release reaction of brain-derived neurotrophic factor (BDNF) through PAR1 activation and its two distinct pools in human platelets. Thromb Res 128(5):e55–e61. (PMID: 10.1016/j.thromres.2011.06.002)
Azoulay D, Mausner-Fainberg K, Urshansky N, Fahoum F, Karni A (2009) Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J Neuroimmunol 211(1–2):114–119. (PMID: 10.1016/j.jneuroim.2009.04.004)
Karczewska-Kupczewska M, Kowalska I, Nikolajuk A et al (2012) Circulating brain-derived neurotrophic factor concentration is downregulated by intralipid/heparin infusion or high-fat meal in young healthy male subjects. Diabetes Care 35(2):358–362. (PMID: 10.2337/dc11-1295)
Chen ZY, Bath K, McEwen B, Hempstead B, Lee F (2008) Impact of genetic variant BDNF (Val66Met) on brain structure and function. Novartis Found Symp 289:180–188. (PMID: 10.1002/9780470751251.ch14)

Keywords: Brain-derived neurotrophic factor (BDNF); Peripheral neuropathy (PN); Val66Met-SNP

0 (Biomarkers)
0 (Brain-Derived Neurotrophic Factor)
7171WSG8A2 (BDNF protein, human)
AE28F7PNPL (Methionine)
HG18B9YRS7 (Valine)

Date Created: 20200304 Date Completed: 20200826 Latest Revision: 20210217

20221213

10.1007/s00592-020-01508-6

32124075